Research
Hormonal
Early discontinuation of GLP-1RA therapy is associated with increased risks of coronary artery disease and heart failure.
Clinicians should be aware of the cardiovascular risks when patients discontinue GLP-1RA therapy early.
StrongSupportsmedium confidence
Early discontinuation (< 1 year) is associated with increased risks of coronary artery disease and heart failure compared with continued therapy.
Why this rating
Based on evidence from randomized withdrawal trials.
Source
Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of <scp>GLP</scp> ‐1 Receptor Agonists
E Abu Shah et al. · Diabetes Obesity and Metabolism · 2026
DOI 10.1111/dom.70713
Meta-analysis
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →